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Abstract
Background: The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and
effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the
antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2)
was investigated.
Methods: Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography.
Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by
plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment,
penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope
(E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically
test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay.
Results: Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration
tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed
that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its
penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection.
Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA
competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity.
Conclusions: Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated
that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus
interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral
treatment, particularly for early phase dengue viral infection.
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Background
The fast spread of dengue pandemic especially in tropical
countries is worrisome. Every year, 390 million individuals
are estimated to be infected with dengue fever, and the oc-
currence is growing [1]. The countries with the highest
disease burden are in the Asia-Pacific region, South and
Central America and the Caribbean [2]. The new WHO
guideline classifies dengue as dengue with or without
warning signs and severe dengue [3]. Dengue is caused by
dengue virus (DENV), which belongs to the family Fla-
viviridae and the genus Flavivirus [2, 4]. DENV has
four antigenically related serotypes named DENV-1,
DENV-2, DENV-3, and DENV-4, each causing similar
series of illnesses ranging from asymptomatic to a self-
limiting febrile illness, to severe and fatal haemorrhagic
disease [5]. DENV is mostly spread through its funda-
mental vector, the Aedes aegypti; which is easily bred in
tropical urban areas packed with human. DENV is
made up of a single-stranded positive-sense RNA genome,
sized about 11,000 nucleotides in length. The genome
bears an icosahedral nucleocapsid core surrounded by a
lipid envelope, wherein the envelope (E) protein and
membrane (M) protein are embedded [2, 6, 7]. The major
E protein, which forms the glycoprotein shell of the virus,
consists of three β-barrel domains namely; Domain I,
Domain II, and Domain III [8]. Domain I contains the N-
terminus, Domain II mediates dimerization of E, while
Domain III is predicted to be involved in receptor binding
and antibody neutralization.
Despite the fast spread of dengue pandemic, there is
currently no vaccine or antiviral drugs that can effectively
prevent or treat dengue infections [9, 10]. However, exten-
sive research is being conducted to validate the ability of
certain natural compounds to inhibit DENV [5, 11, 12].
As in other viruses, DENV has several stages in their rep-
lication cycle that can be the target for antiviral drugs de-
sign. Natural products are promising sources of novel
antivirals as they have a variety of chemical constituents
that can inhibit the replication cycle of various types of
DNA or RNA viruses [13]. Nephelium lappaceum is an
evergreen tree which is abundant in tropical countries
such as Malaysia, Indonesia, Philippines, Thailand and
several other regions of the Southeast Asia. Nephelium
lappaceum belongs to the family Sapindaceae [14] and
its fruits are normally eaten raw while the seed and rind
are discarded. Geraniin was identified as the major
compound found in the extract of Nephelium lappa-
ceum rind [15]. Geraniin is an ellagitannin, which
belongs to the hydrolysable tannin group and occurs
naturally in foods such as raspberries, strawberries,
blackberries, pomegranate, almonds, and walnuts [16].
Ellagitannins are compounds with a complex chemical
structure and have diverse physical properties that lead
to various health benefits [17].
Geraniin is present in different parts of various types
of plants and has been shown to exhibit antiviral proper-
ties against several types of viruses. The compound iso-
lated from Phyllanthus urinaria Linnea was shown to
actively suppress HSV-1 and HSV-2 infection at different
magnitudes of activity [18]. Notka et al. [19] had shown
that geraniin extracted from Phyllanthus amarus plant
had the ability to effectively inhibit HIV-1 replication.
Geraniin was identified as one of the active ingredients
from the ethanol extract of Geranium carolinianum L., a
domestic plant grown in China, to exhibit anti-HBV ac-
tivity [20]. It was also shown that geraniin could effect-
ively inhibit the human enterovirus 71 replications in
RD cells and increased the survival rate of infected mice
[21]. To date, there are no reports on the specific use of
geraniin to inhibit DENV. However, in a study con-
ducted by Lee et al. [11], it was reported that a cocktail
of extracts from four species of Phyllanthus showed a
strong inhibitory activity against DENV-2 and geraniin
was found to be the largest component in the extract.
Dengue has become one of the most important
arthropod-borne viral diseases and a major public health
concern due to the speed of its spread, together with the
escalating seriousness of its complications [22]. Unfortu-
nately, despite the advancement of today’s research and
development, not even one anti-dengue drug has been ap-
proved. Hurdles such as incomplete understanding of
dengue pathogenesis and poor funding in the develop-
ment of anti-dengue drugs were thought to contribute to
its absence [23]. Since dengue is marked as a disease of
poverty [21], the cost of a drug is also going to be a main
issue. Hence, it is important that the source of antiviral
molecules be cost-effective, which can be achieved by
selecting easy to synthesize chemical scaffolds, or by
unearthing the active natural compounds and choosing
those that represent major chemical constituents of suit-
ably available plants [24]. As geraniin used in this study
was extracted from the rind of Nephelium lappaceum,
which is considered a waste product, its usage as a source
for anti-dengue drug satisfies the cost-effectiveness re-
quirement of an antiviral drug. Previous reports on gera-
niin’s antiviral activity against several prominent viruses
provides evidence that this compound can be effectively
used in antiviral therapeutics. Given the need to find an
antiviral against DENV, and geraniin’s potential to be
developed as a compound of interest, our study aims to
investigate the in vitro inhibition of DENV-2 by geraniin
and elucidate its mechanistic behavior.
Methods
Preparation of geraniin from Nephelium lappaceum L. rind
by reverse phase C-18 column chromatography
Nephelium lappaceum L. was obtained from Kuala Lumpur,
Peninsular Malaysia and plants were authenticated by the
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Herbarium of the Forest Research Institute of Malaysia
(FRIM). Crude ethanolic extract of Nephelium lappa-
ceum L. rind was prepared as described by Palanisamy
and co-workers. Geraniin was purified from the crude
extract by means of reverse-phase chromatography
[14]. Crude extract (20 g) was dissolved in a minimum
amount of water (40 mL) and loaded onto glass column
(250 mm × 50 mm i.d.) packed with 200 g C18 silica
(particle size 50 μm, pore size 60 Å). The column was
open-tubular and solvent flow rate was maintained by
means of vacuum pump attached to vacuum inlet in
the column. The column was first eluted with water
(300 mL) and then fractions were collected using a step
gradient of water and acetonitrile. Solvent system was
as follows; water (100%, 400 mL), acetonitrile: water
(5:95, 350 mL), acetonitrile: water (10:90, 1000 mL).
Finally, the column was eluted with methanol (100%,
500 mL). The silica was cleaned by flushing the column
sequentially with dichloromethane (100%, 300 mL),
methanol containing a few drops of TFA (100%, 300 mL)
and absolute methanol (100%, 300 mL), allowing to dry
completely. This enables the column to be reused with
fresh crude extract. Purity of geraniin (> 95%) obtained
was confirmed using HPLC [25]. For use in cell culture,
geraniin was initially dissolved in 0.2% dimethyl sulfoxide
(DMSO; Sigma-Aldrich; St. Louis, MO, USA) and diluted
in minimum essential medium (MEM) containing 2% fetal
bovine serum (FBS) (Gibco®; Life Technologies, Carlsbad,
CA, USA) to the required concentration, immediately
prior to the experiments.
Cell culture and virus
Propagation of DENV-2 was conducted in African Green
Monkey kidney cells (Vero) (ATCC CCL-81). The cells
were maintained at 37 °C with 5% CO2 and propagated
in MEM supplemented with 10% FBS, HEPES buffer
and penicillin/streptomycin (Gibco®). DENV-2 (accession
no: AJ556810.1) was kindly provided by Prof. Sazaly AB
(University of Malaya, Malaysia). Its titer was expressed
as plaque forming unit (PFU) per ml. Virus stocks were
stored at -80 °C until use.
Cytotoxicity assay
Vero cells (5 × 104 cells/ml in 96-well-plates) were
treated with various concentrations of geraniin for
24 h at 37 °C in 5% CO2. Cell viability (%) was then
assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide, Sigma-Aldrich; St.
Louis, Missouri, USA) assay as described by Javed et
al. [26]. Absorbance was measured at 560 nm (OD560)
using a microplate reader (Bio-Rad; Hercules, CA,
USA). All experiments were performed in triplicates
and repeated three times.
Plaque reduction assay
Plaque reduction assay was carried out under two differ-
ent conditions according to Meneses et al. [27], with
minor modifications.
1) Incubation of geraniin with DENV-2 before
adsorption: Vero cells (2 × 105 cells/ml in 24-well-
plate) were incubated to at least 95% confluency.
DENV-2 suspension, with approximately 90–100
plaques per well, was mixed with or without
varying concentrations of geraniin. This suspension
was incubated at 37 °C for 1 h in MEM containing
2% FBS, before being adsorbed onto cells at 37 °C
for 1 h. The mixture was removed and replaced
with overlay medium containing MEM with 1% FBS,
HEPES, antibiotics and 1% carboxymethyl-cellulose
(CMC; Sigma-Aldrich). After a 5-day incubation, the
cells were fixed with 10% formalin, followed by
staining with 1% crystal violet and plaques counted.
The percentage of plaque inhibition compared with
controls without geraniin, was calculated according
to Cheng et al. [28]. The minimal concentration of
geraniin required to reduce 50% plaque number
(IC50) was deduced from the dose-response curve
using GraphPad Prism 5 software (GraphPad
Software, Inc.; La Jolla, CA 92037, USA).
2) Incubation of geraniin with cells before adsorption:
Vero cells (2 × 105 cells/ml in 24-well-plate) were
incubated to at least 95% confluency. The cells were
incubated with or without varying concentrations of
geraniin at 37 °C for 1 h. Geraniin was then washed
off from the plate using PBS and cells were infected
with DENV-2 suspension, with approximately
90–100 plaques per well, by adsorption at 37 °C
for 1 h. The plate was washed and medium replaced
with overlay medium. After 5 days, the cells were
fixed and stained using the same procedure described
above and plaque number counted.
Virucidal assay
This assay was conducted to investigate the virucidal
effect of geraniin on DENV-2, according to Cheng et al.
[27], with minor modifications. Briefly, a virus suspen-
sion containing 6.74 × 104 PFU/ml DENV-2 was mixed
with or without various concentrations of geraniin for
6 h at 26 °C (room temperature). The samples were
subjected to a ten-fold serial dilution, titrated onto con-
fluent monolayer Vero cells (in 24-well plate) and
adsorbed at 37 °C for 1 h. The mixture was removed
and replaced with overlay medium. After a 5 day incu-
bation, the cells were fixed with 10% formalin followed
by staining with 1% crystal violet, and plaques formed
were counted. The residual infectivity of each sample
was expressed as PFU/ml.
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Attachment assay
This assay was conducted according to a published
procedure by Cheng et al. [27], with minor modifica-
tions. Briefly, Vero cells were grown in 24-well-plate
and pre-chilled at 4 °C for 1 h. Cells were infected
with DENV-2 exhibiting 90–100 plaques per well in
the absence or presence of various concentrations of
geraniin at 4 °C for 3 h. After washing with PBS for
three times, the cells were overlaid with overlay
medium and incubated at 37 °C for 5 days before be-
ing fixed and stained. The percentage of plaque inhib-
ition was estimated.
Penetration assay
This assay was conducted according to a published pro-
cedure by Cheng et al. [27], with minor modifications.
Briefly, Vero cells were grown in a 24-well-plate and
pre-chilled at 4 °C for 1 h. Cells were infected with
DENV-2 exhibiting 90–100 plaques per well and incu-
bated at 4 °C for another 3 h, to allow the attachment of
DENV-2 toward cell monolayer. After 3 h, geraniin was
added to the wells, with the exception of control, and in-
fected cells were incubated at 37 °C for maximal viral
penetration. At every 10 min interval, infected cells were
treated with PBS, pH 3 for 1 min to inactivate un-
penetrated virus. The acidic media was neutralized using
PBS, pH 11, which was then removed and replaced with
overlay medium. After further incubation at 37 °C for
5 days, the cells were fixed and stained and its plaque in-
hibition estimated.
Kinetics of DENV-2 RNA synthesis by quantitative RT-PCR
Vero cells in 24-well-plate were infected with 6.74 × 104
PFU/ml DENV-2. After a 1 h adsorption at 37 °C, the
viral inoculum was removed and MEM supplemented
with 2% FBS was added and further incubated at 37 °C.
At selected intervals of post-infection, total intracellular
viral RNA was extracted using TRI Reagent® Solution
(Molecular Research Center, Inc.; Cincinnati, OH,
USA) as instructed by the manufacturer. For quantita-
tive RT-PCR (qRT-PCR), a two-step protocol was
employed. First, cDNA was synthesized using Maxima
First Strand cDNA Synthesis Kit (Fermentas, Thermo
Fisher Scientific Inc.; Waltham, MA, USA); second, am-
plifications were carried out using KAPA SYBR® FAST
qPCR Master Mix (KapaBiosystems; Woburn, MA,
USA) with the primer pairs designed from conserved
region of DENV-2 E gene: forward 5′-GGCCTCGACT
TCAATGAGATGG-3′ (1482–1503), reverse 5′-CCTG
TTTCTTCGCATGGGGAT-3′ (1639–1659 complement)
using ABI Step One and Step One Plus Real Time PCR
Systems (Applied Biosystems; Foster City, CA, USA).
Cycles consisted of an initial incubation step at 94 °C for
2 min, 40 cycles at 94 °C for 30 s, 60 °C for 30 s, and 72 °C
for 30 s, and a melting curve analysis cycle. Absolute quan-
tification of DENV-2 viral load was determined using the
standard curve, generated from 10-fold serial dilutions of a
plasmid containing DENV-2 gene. All determinations were
performed in technical triplicates.
Time-of-addition assay
This assay was modified from the procedure published
by Daelemans et al. [29]. Vero cells in 24-well-plate
were infected with 6.74 × 104 PFU/ml DENV-2. After a
1 h adsorption at 37 °C, the excess unbound virus was
removed and replaced with MEM supplemented with
2% FBS. The compound, 7-deaza-2′-C-methyladeno-
sine (Santa Cruz Biotechnology, Inc.; Dallas, Texas,
USA), which inhibits DENV NS5 polymerase at a later
stage of the virus life cycle [30], was used as a positive
control in this study. Geraniin (210 μM) or 7-deaza-
2′-C-methyladenosine (100 μM) were added at differ-
ent time intervals (0, 2, 4, 8, 12, 14, 16, 24 h) after
infection. At 48 h post-infection (h p.i.), the cells were
collected and intracellular viral RNA extracted for viral
load quantification using the two-step qRT-PCR de-
scribed earlier. The percentage of viral RNA inhibition
in treated samples compared with untreated controls
were calculated.
Molecular docking
Docking of geraniin to DENV-2 E protein was conducted
using the program AutoDock Vina [31]. The three-
dimensional structure of DENV-2 E glycoprotein structure
was retrieved from the Protein Data Bank (PDB entry:
1OKE) while the structure of geraniin was retrieved from
ChemSpider database (http://www.chemspider.com).
Production of recombinant E-DIII protein
The DENV-2 E gene was amplified using the DENV-2 as
template and cloned in-frame and sequenced for its
integrity in pCR® 2.1-TOPO TA vector (Invitrogen™, Life
Technologies; Carlsbad, CA, USA). The E-DIII was ampli-
fied (forward primer: CTGGTACCCTCAAAGGAATGT-
CATAC, reverse primer: TCGAATTCTTAACTTCCTT
TCTTAAACCA, restriction digestion sites underlined),
and cloned in-frame into a pRSET-B protein expression
plasmid (Invitrogen™, Life Technologies). This clone was
identified as pRSETB-EIII. The DNA of pRSETB-EIII was
sequenced for the detection of missense and nonsense
mutation. For E-DIII expression, pRSETB-EIII was ex-
tracted and transformed into E. coli BL21 (DE3) strain.
Single survived colony was sub-cultured into 500 mL of
Luria-Bertani (LB) broth supplemented with ampicillin
(100 μg/mL). The culture was maintained in a shaking in-
cubator (37 °C, 150 rpm) until an OD600 of 0.5, this was
followed by the addition of IPTG (working concentration
of 0.5 mM) to induce E-DIII protein expression and the
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culture was further incubated for 3 h (30 °C, 150 rpm).
The bacterial cells were pelleted, and lysed in HEPES buf-
fer (25 mM) using a cell sonicator probe (180 pulse,
3 min). The inclusion bodies were solubilized in urea
(8 M) and purified with HisPur Ni-NTA Resin Kit
(Thermo Fisher Scientific, Life Technologies) according to
the manufacturer’s instructions.
ELISA competitive binding assay
Saturation binding assay: An ELISA plate was coated with
rE-DIII protein dissolved in 0.1 M carbonate-bicarbonate
buffer (pH 9.5), and incubated overnight at 4 °C. The plate
was washed with TBS containing 0.05% Tween 20 (TBST)
and blocked with 1% BSA in TBS (BTBS) at room
temperature for 3 h. After washing, the plate was incubated
at room temperature for 2 h with serial dilutions of the
DENV E-D3 monoclonal antibody, clone 5j122 (MAB8901,
Abnova; Taipei, Taiwan) in TBS containing 1% BSA and
0.05% Tween 20 (BTBST). The plate was then washed with
TBST and treated with Anti-Mouse IgG (Whole Molecule)
Alkaline Phosphatase Conjugate (A5153, Sigma-Aldrich) in
BTBST. After a 1 h incubation at room temperature, the
plate was washed with TBST and the binding of monoclo-
nal antibody (mAb) to rE-DIII protein was monitored by
calorimetric assay using p-Nitrophenyl phosphate (pNPP)
as substrate (Sigma-Aldrich). After a 30 min incubation,
the absorbance was measured at 405 nm using a plate
reader (Bio-Rad). Binding curve and Kd (equilibrium dis-
sociation constant) value for the mAb was determined fol-
lowing nonlinear regression analysis on GraphPad Prism 5
software.
Competitive binding assay: An ELISA plate was
coated with rE-DIII protein (6.3 μg/ml) dissolved in
0.1 M carbonate-bicarbonate buffer, and incubated
overnight at 4 °C. The plate was washed with TBST and
blocked with BTBS at room temperature for 3 h. After
washing, the plate was incubated for 2 h at 37 °C with
various concentrations of geraniin diluted with BTBST.
Geraniin was discarded and the plate was washed with
TBST. The plate was then incubated at room temperature
for 2 h with a single concentration of DENV E-D3 mAb,
clone 5j122 in BTBST. The plate was then washed with
TBST and treated with Anti-Mouse IgG Alkaline Phos-
phatase Conjugate in BTBST. After a 1 h incubation at
room temperature, the plate was washed with TBST and
the binding of mAb to rE-DIII protein was monitored
using pNPP as substrate. After a 30 min incubation, ab-
sorbance was measured at 405 nm. The competitive bind-
ing curve and Ki (inhibitory constant: the concentration of
a ligand that will bind to half the binding sites at equilib-
rium in the absence of a competitor ligand) value of
geraniin was determined following nonlinear regression
analysis on GraphPad Prism 5 software.
Statistical analysis
The software GraphPad Prism (Version 5.0) was used
for all statistical analysis and graphical illustrations. The
statistical significance of the difference between mean
values was determined by Student’s t-test. The signifi-
cant difference was considered as P < 0.05.
Results
Effect of geraniin on DENV-2 plaque formation
MTT assay was conducted to determine the cytotoxicity
of geraniin towards Vero cells. Figure 1 shows that gera-
niin was not toxic to Vero cells even at the highest
tested concentration of 2 mM. To determine the anti-
viral activity of geraniin, plaque reduction assay was car-
ried out under two different conditions; incubation of
geraniin with DENV-2 before adsorption and incubation
of geraniin with cells before adsorption. Compared with
control (without geraniin), plaque formation was signifi-
cantly reduced when geraniin was incubated with
DENV-2 before adsorption. The percentage of plaque in-
hibition was calculated and dose-response curve gener-
ated from the data obtained. Figure 2a shows that when
geraniin was incubated with DENV-2 before adsorption,
DENV-2 plaque formation was inhibited in a dose-
dependent manner, with an IC50 of 1.75 μM. However,
no inhibition in plaque formation was observed when
geraniin was incubated with cells before adsorption
(Fig. 2b).
Mode-of-action of geraniin
Although the plaque reduction assay indicated that gera-
niin was a DENV-2 inhibitor, it was unable to provide
information on the mode-of-action of this compound.
Therefore, further studies were conducted to determine
at which stage geraniin affected the viral life cycle.
Fig. 1 Cytotoxicity assay of geraniin. Geraniin was not toxic to Vero
cells even at the highest concentration tested; hence validate its use
in the antiviral assays. Data are shown as the mean ± SEM of
triplicate from one independent experiment
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Virucidal assay was carried out to investigate the effect
of varying geraniin concentration on viral residual in-
fectivity. Residual infectivity represents the amount of
virus that was not disrupted by geraniin, and hence can
still infect cells and replicate. As shown in Table 1, gera-
niin reduced the infectivity of DENV-2 up to 102 PFU/
ml at a concentration of 3.28 μM. Geraniin at concentra-
tions lower than 1.64 μM had no virucidal effect on
DENV-2. The virucidal assay confirmed that geraniin
reduced the infectivity of DENV-2 in a dose-dependent
manner. The attachment assay, on the other hand, was
carried out to investigate the effect of geraniin on the
attachment of DENV-2 to Vero cells. Figure 3 shows
that DENV-2 attachment was significantly inhibited by
geraniin in a dose-dependent manner, with a 100% in-
hibition at the concentration of 26.3 μM. The penetra-
tion assay was used to investigate the ability of geraniin
to inhibit attached DENV-2 from entering cells. Figure 4
shows that geraniin did not have a significant effect on
viruses already attached to cells, and inhibited viruses
only in the range of 5–40%.
Geraniin affects early stages of DENV-2 replication
Time-of-addition assay was carried out to elucidate the
stage at which geraniin affected the viral life cycle. The
point where geraniin exerts its inhibitory effect during
DENV-2 replication cycle may be explicated by determin-
ing the effect of different time-of-addition of geraniin on
DENV-2 infected cells. To determine this, the time-course
kinetic of DENV-2 replication in Vero cells without gera-
niin treatment must be known. The kinetic of DENV-2
Fig. 2 Inhibitory effect of geraniin against DENV-2. a A dose response
curve showing concentration-dependent inhibition of DENV-2 plaque
formation when geraniin was incubated with DENV-2 before
adsorption. b A dose-response curve indicating that geraniin
caused no inhibition towards DENV-2 plaque formation when it
was incubated with cells before adsorption. Percentage of plaque
inhibition was calculated, and the data was incorporated into the
GraphPad Prism 5 software to obtain the IC50 values. Data represent
mean values ±SEM
Table 1 Effect of varying geraniin concentrations on DENV-2
residual infectivity
Concentration of Geraniin (μM) Residual Infectivity (PFU/ml)
0 5.18 × 105
0.41 5.15 × 106
0.82 5.55 × 107
1.64 3.93 × 107
3.28 4.95 × 105
6.57 5.20 × 104
13.13 5.75 × 104
26.26 5.55 × 104
52.52 5.78 × 104
105 3.88 × 104
Virucidal effect of geraniin on DENV-2 was studied by quantifying the infectiv-
ity of DENV-2 that remained after it has been exposed to geraniin. DENV-2
with a titer of 6.74 × 106 PFU/ml was used on varying geraniin concentrations
for 6 h at 26 °C and the residual infectivity determined
Fig. 3 Effect of geraniin on the attachment of DENV-2 to Vero cells.
Vero monolayer was pre-chilled at 4 °C for 1 h. DENV-2 was inoculated
to Vero monolayer in the absence (virus control) or presence of
geraniin and incubated at 4 °C for another 3 h. The dose-response
curve indicates the inhibition of DENV-2 attachment to Vero cells by
geraniin. Data represent mean values ±SEM
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RNA synthesis in infected Vero cells was examined
quantitatively by determining the amount of intracellu-
lar DENV-2 RNA using the SYBR Green based qRT-
PCR amplification. Our results show that the intracellu-
lar DENV-2 RNA can be detected up to 120 h p.i.
(Fig. 5a). Within the first 0–16 h p.i., there was no in-
crease in RNA copy number, while a gradual increase
was observed from 16 to 40 h p.i., followed by a signifi-
cant increase at 48 h p.i. The RNA copy for DENV-2
increased from around 104 copies/μl at 40 h to 105 cop-
ies/μl of RNA at 48 h, as detected by qRT-PCR. The
RNA copy number continued to increase up until the
120th h with a value of about 107 copies/μl of RNA.
Henceforth, virus growth and replication during the
time-of-addition assay was allowed for 48 h for suffi-
cient virus production. In this assay, geraniin was added
to DENV-2 infected Vero cells either during the time of
infection or at several time points after infection. From
the graph shown in Fig. 5b, a constant inhibition of al-
most 100% was observed throughout the experiment
when control compound (7 deaza-2′-C-methyladeno-
sine) was used; retaining its antiviral activity even when
added at 24 h p.i. In contrast, geraniin saw a 100% in-
hibition when added at 0 h p.i., followed by a significant
inhibition of about 90% up until when geraniin was
added at 16 h p.i. and dropped to about 50% inhibition
when geraniin was added at 24 h p.i. Geraniin treat-
ment therefore markedly reduced DENV-2 replication
especially at earlier time points or at early stage of
infection.
Geraniin binds to domain III of E protein
Docking of geraniin (molecular weight: 952.64 g/mol) was
carried out on DENV-2 E protein. Geraniin was shown to
bind to domain III of DENV-2 E protein, spanning from
amino acid residues 296–394, at a binding affinity of
−9.8 kcal/mol. The binding pose of geraniin on DENV-2 E
protein is shown in Fig. 6a, while its interaction with the
amino acid residues of the protein is shown in Fig. 6b.
The binding site of geraniin to E-DIII is between amino
acid residues 334–356. To physiologically prove the bind-
ing of geraniin to DENV-2 E-DIII protein, a rE-DIII pro-
tein was produced. SDS-PAGE confirmed the successfully
expression and purification of E-DIII protein (Fig. 7a, b).
The single band at the expected size (15 kDa) of the puri-
fied E-DIII protein was excised and subjected to in-gel
tryptic digestion before it was analyzed on LC-MS/MS to
validate its identity and authenticity. Agilent Spectrum
Mill search results showed significant hits for DENV-2
polyprotein and the targeted DENV E protein, which con-
firmed the identity of the purified rE-DIII protein. Binding
of geraniin to the rE-DIII protein was then confirmed
through a competitive-binding ELISA using a mAb that
recognizes recombinant protein corresponding to amino
acids 301–400 of DENV E-DIII as the reference analyte.
To determine the binding affinity of this mAb for its re-
ceptor on our rE-DIII protein, saturation binding assay
was conducted. Through this assay, the Kd value of the
mAb needed to carry out the competitive binding assay,
was determined. Figure 7c shows the binding curve of this
mAb to the rE-DIII protein. The Kd value of the mAb, as
determined through nonlinear regression analysis was
0.31 nM. A ligand binding with a Kd of 1 nM or less is
generally considered to have a high affinity for its receptor,
whereas ligands binding with a Kd of 1 μM have low affin-
ity [32]. The high affinity of this mAb for the binding site
on rE-DIII provides a stronger competition for geraniin as
a ligand to the rE-DIII in the competitive binding assay.
Having determined the Kd value of the reference analyte,
the Ki value of the competing analyte (geraniin) was then
determined through the competitive binding assay. The
aim of this competitive assay is to determine the Ki or the
equilibrium inhibitor constant of geraniin. Geraniin was
Fig. 4 Effect of geraniin on the penetration of DENV-2 into Vero cells. Vero monolayer was pre-chilled at 4 °C for 1 h and then infected with
DENV-2 at 4 °C for another 3 h. After 3 h incubation, geraniin was added. At 10 min interval, extracellular virus was killed by PBS at pH 3. PBS
at pH 11 was then added to neutralize acidic PBS. The graph of percentage of DENV-2 plaque inhibition was plotted against time taken for
penetration. Data represent mean values ±SEM
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allowed to bind to the rE-DIII protein coated-plate before
incubation with the mAb. It is assumed that geraniin
binding to the rE-DIII, will block the mAb from binding
to the rE-DIII protein, resulting in a lower ELISA absorb-
ance values. Based on the result in Fig. 7d, it was shown
that geraniin does bind to rE-DIII with a Ki value of
55.19 nM. As the concentration of geraniin increases, the
binding of mAb to the rE-DIII protein decreased. This in-
dicates that geraniin binding to the rE-DIII protein had
prevented the mAb from binding to its neutralization site
on the rE-DIII protein.
Discussion
Geraniin was first isolated in 1976 by Okuda et al., from
the leaf extracts of Geranium thunbergii Sieb. et Zucc.;
an official anti-diarrheic and one of the most frequently
used folk medicines in Japan [33]. Since then, the occur-
rence of geraniin has been confirmed in at least 71 dif-
ferent plant species from 26 genera and across 9 families
[34]. Here, we assess the effectiveness of geraniin ex-
tracted from the rind of Nephelium lappaceum against
DENV-2. Although DENV has four different serotypes,
we chose to work only on DENV-2 since this serotype is
more likely to be related to the severe form of dengue. It
was observed that patients who are infected with
DENV-2 experienced more severe disease and had a
higher chance of having dengue haemorrhagic fever
(DHF) than those infected with other serotypes [35].
DENV-2 was also responsible for several major dengue
outbreaks in Malaysia. DENV-2 emerged as a major
serotype in Malaysia in the late 1960s until the early
1970s, and has since persisted in the country, causing
major outbreaks that occurred in late 1980s to early
1990s and the subsequent outbreak in late 1990s to early
2000s [36].
The inhibitory potential of geraniin against DENV-2
was first tested using plaque reduction assay, which is
considered as the ‘gold standard’ for determining anti-
viral activity of selected agents against certain viruses
[37]. It directly measures the extent to which an antiviral
drug inhibits the effect of viral infections in cell culture.
Our results from this experimentation implied that gera-
niin inhibited DENV-2 by affecting either the virus par-
ticle itself (virucidal), or by binding to the viral receptors
that are involved in the attachment or penetration of
virus into cells. However, since no inhibition was ob-
served when geraniin was incubated with the cells before
adsorption, it was believed that geraniin’s antiviral activ-
ity does not involve the cellular receptors. Adsorption of
the virus to cells involves two major steps in the viral life
cycle; attachment and penetration. The plaque reduction
assay was not able to determine which one of these two
steps or both, were involved in the inhibition process. In
order to elucidate this, mode-of-action experimentations
involving virucidal, attachment, penetration and time-of-
addition assays’ were carried out.
Chemical substances are regarded as virucidal agents if
they are able to inactivate the extracellular viral particles
by damaging the protein coat or penetrating the virion and
destroying the viral genome; hence, resulting in decreased
infectivity of the virus [38]. The possibility of this occurring
was demonstrated using a virucidal assay, where geraniin
binding to the virus was shown to have decreased infection
and viral replication. Geraniin could either be affecting the
structural built-up of the DENV particle, which is made up
of C, prM, and E proteins; or it could be affecting the viral
Fig. 5 Effect of geraniin on the time of addition. a DENV-2 Replication
in Vero cells. Vero cells were infected with 6.74 × 104 PFU/ml DENV-2.
At selected intervals, intracellular RNA was isolated and DENV-2 RNA
levels were quantified using SYBR Green dye-based qRT-PCR assay.
Plotted absolute number of viral RNA copy in log scale per μl of RNA
used for qRT-PCR. (b) Geraniin or the control compound was added to
DENV-2 infected Vero cells at different time points after infection.
Addition of compounds was conducted up to 24 h before the cells
were harvested at 48 h p.i. Samples were subjected to RNA extraction
and later to two-step qRT-PCR. Absolute quantification of viral load in
treated samples was conducted using the standard curve method.
Percentage of inhibition was calculated based on the amount of viral
RNA in treated samples compared with untreated controls. Geraniin
was effective in inhibiting DENV-2 RNA synthesis when it was added
at earlier time-points post-infection. Data represent mean values ±SEM
Abdul Ahmad et al. Virology Journal  (2017) 14:229 Page 8 of 13
genome and destroying the virus from inside out. The
questions of whether geraniin exerts its antiviral effect ei-
ther by entering cells or acting extracellularly remains un-
answered [39]. However, the fact that geraniin is a rather
large molecule (952.64 g/mol) and being charged, makes it
difficult to enter the virion and destroy the genome. It
would seem more plausible that geraniin acts extracellu-
larly and at high geraniin concentrations there is an
increased probability of its interaction with the virion or its
extracellular viral particles. This results in the disruption of
infection thus contributing to the decreased infectivity of
DENV-2 as seen in our virucidal assay experimentations.
The attachment and penetration assays’ were carried
out to study the effect of geraniin on the attachment and
penetration of DENV-2 to Vero cells. These assays are
dependent on the different temperature requirements of
Fig. 6 Molecular Docking. a Binding pose of geraniin’s molecular structure on DENV-2 E protein (PDB entry: 1OKE). Arrow indicates the molecular
structure of geraniin. Domain III is marked blue and a putative receptor-binding loop in domain III is marked red. b Interaction of geraniin with
the amino acid residues of DENV-2 E protein as shown by docking. Geraniin binds at domain III of E protein which ranges from amino acid
residues 296–394, by forming a hydrogen bond with the amino acid residues of the E protein
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these two initial steps in the viral life cycle. Viral attach-
ment can occur at both 4 °C and 37 °C, while viral pene-
tration can only proceed at 37 °C [3], hence these two
steps can be investigated in separate experiments. In the
attachment assay, cells were exposed to virus and geraniin
at 4 °C, where the virus only attaches to cells, without
penetrating them. Plaque formation here was significantly
reduced, indicating that geraniin had either prevented
DENV-2 attachment to cells or prevented attached
DENV-2 from entering cells. The penetration assay con-
firmed that geraniin did not have a significant effect if
present post viral attachment. Our findings propose that
geraniin inhibits DENV-2 by disrupting the attachment of
the virus with host cellular receptors.
Compounds that can inhibit attachment and prevent
entry of pathogenic microbes are appealing because such
drugs will not have to gain access to the interior of cells
and are therefore expected to display increased bioavail-
ability [40]. In a study carried out by Weaver et al. [41],
they proposed the mechanism of action of several
tannins against HIV. They showed the tannins ability to
significantly block the binding of recombinant HIV coat
protein gp120 to its normal cellular receptor CD4. They
observed that some of the tannins were required to be
present, at the time of infection, in order to exert its
potent anti-HIV activity. Similar findings were observed
in our study, where a 100% inhibition was observed in
the time-of-addition assay upon geraniin’s addition at
the time of infection (0 h p.i.). This strengthens our
postulation that geraniin exerts its effect by blocking
DENV-2 adsorption.
The time-of-addition study suggests the viral life cycle
stage that is affected by an inhibitor. In addition, the














Fig. 7 Binding of geraniin to recombinant DENV-2 E Domain III protein. a SDS-PAGE gel showing expression of DENV-2 E-DIII protein. Lane M
indicates the 10 kDa protein ladder, Lane 1- protein induced with IPTG; Lane 2- protein induced with IPTG; Lane 3- uninduced protein. Size of E-
DIII protein is 15 kDa. b SDS-PAGE gel showing purification of DENV-2 E-DIII protein. Lane M-10 kDa protein ladder; Lanes; 1-pellet, 2-supernatant,
3-flow-through, 4-wash 1, 5-wash 2, 6-wash 3, 7-eluent. A single band at the expected size indicated that the recombinant protein obtained was
pure. c The saturation binding curve obtained when recombinant E-DIII protein was coated onto ELISA plate and was allowed to bind to different
concentrations of monoclonal antibody, clone 5j122 (MAB8901) before the signal was detected using an AP conjugated secondary antibody. The
Kd value of the mAb was determined from the curve by nonlinear regression using GraphPad Prism 5 software. d The competitive binding curve
was obtained through non-linear regression analysis using GraphPad Prism 5 software. The same monoclonal antibody (MAB8901) was used at
one constant concentration of 3.33 nM while various concentrations of geraniin was used to test the ability of geraniin to bind to the recombinant
E-DIII protein, given that the Kd value of the mAb was known. Data represent mean values ±SEM
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replication cycle of DENV-2, can be defined through
this assay [42]. Our findings indicate that geraniin im-
posed its antiviral effect at the early stage of DENV-2
life cycle, between 0 and 16 h p.i. when viral attach-
ment to its cellular receptors occur prior to its entry
into the cytoplasm [43, 44]. This proves that geraniin
exerts its antiviral activity towards DENV-2, through
the mechanism of inhibiting viral attachment. Since
early events in DENV life cycle primarily involves E
protein, this protein is suggested the most likely target
of inhibition by geraniin. E protein also plays a major
role in the control of infection and tropism [43], as well
as being involved in several other interactions such as
with cellular attachment molecules, which are import-
ant for Flavivirus entry [7]. These interactions provide
promising targets for the design of viral entry inhibitors.
Since the attachment of DENV to host cellular receptors
is mediated by the E protein [45], we hypothesize that ger-
aniin interferes with the function of E protein during the
viral life cycle.
Geraniin is a hydrophobic molecule with a logP value
of 3.4. However, when geraniin binds to DENV E pro-
tein, the polar and charged interactions overcome the
hydrophobic interactions between ligand and protein,
due to the presence of multiple hydroxyl groups in the
geraniin molecule. Therefore, from a pharmacological
point of view, geraniin is a good lead for designing an ef-
fective drug in a way that the molecule is sufficiently
hydrophobic to cross the cell membrane and in the same
time, it has a certain number of polar groups to create
significant interactions with DENV E protein. Docking
studies were carried out to provide evidence of geraniin’s
inhibitory effect on DENV E protein. The host cellular
or receptor proteins that bind to the E proteins during
attachment have been identified to be within the Do-
main III region [46]. The docking results showed that
the pocket in which geraniin binds to the E-DIII protein
is in very close vicinity to the putative receptor-binding
loop situated at residue 382–385, which has been associ-
ated with the binding process of DENV to receptors [47].
Domain III is an IgC-like module, with ten β-strands. The
structure of the four residues of the receptor binding-loop
forms a compact solvent-exposed bulge, which is situated
between two strands of Domain III. Since geraniin binds
near the putative receptor binding loop, there is a possibil-
ity that the binding had caused some disturbance on the
conformation of the loop and subsequently disrupts the
binding of Domain III during DENV infection process.
The docking study serves as an impetus for further in-
vestigations into the interaction between geraniin and
DENV E protein. To substantiate docking results and
provide further evidence of geraniin–DENV-2 E-DIII
protein interaction, the rE-DIII protein was produced
recombinantly. The addition of geraniin inhibited mAb
from binding to the rE-DIII protein site. The findings
suggest that either geraniin and the mAb bind to the
same site on the rE-DIII protein or that geraniin binds
at a different site and changes the conformation of rE-
DIII protein hence preventing mAb from binding.
Nevertheless, our findings strongly suggest that geraniin
binds to DENV-2 E-DIII protein with high affinity with
validation from docking studies.
Initial interaction of viruses with target cells is based
on specific receptor-ligand interactions between surface
structures [48]. For DENVs, the initial binding to target
host cells is mediated by binding of the E protein to spe-
cific cell surface receptor/s resulting in viral replication
and pathogenesis [49]. Molecules that can disrupt virus-
host binding and inhibiting the entry of the virus parti-
cles into target cells [50] would be considered as very
specific inhibitors. The most effective way of preventing
viral infection is by blocking the cellular receptors or by
using compounds that will bind to the virus receptors’
binding domains, hence preventing the virus from bind-
ing to the cellular receptors. The latter approach is pre-
ferred since toxicity towards host cells can be avoided.
Overall, our study had proven that geraniin extracted
from the rind of Nephelium lappaceum has antiviral activ-
ity against DENV-2. The mode of its action is either
through binding or possibly disruption to the DENV E
protein, thus inhibiting viral attachment to cellular recep-
tors during the early stages of the virus life cycle. The
binding of geraniin to E-DIII prevents protein-protein
interaction between DENV-2 and host cells during infec-
tion, thus preventing the attachment and entry process.
The exploration of geraniin to be developed into an effect-
ive early antiviral treatment for DENV is in line with the
current focus on therapeutic strategy for inhibiting envel-
oped viruses, that is, through the intervention of the viral
entry step [29].
Conclusions
Our study establishes that geraniin has antiviral activity
against DENV-2 by inhibiting the mechanism of viral at-
tachment. It most likely shows its effect through the E
protein during early stages of the virus life cycle and hence
suppresses early viral gene transcription and replication.
However, the precise mechanism by which geraniin in-
hibits DENV-2 gene transcription is still unknown and
needs to be further investigated. In vivo experiments to
determine the efficacy of geraniin to protect mice from
DENV-2 challenge would be beneficial as it can affirm
geraniin’s capability to be further developed as an effective
anti-dengue agent.
Abbreviations
ATCC: American Type Culture Collection; CMC: Carboxy-methyl cellulose;
CO2: Carbon dioxide; DENV: Dengue virus; DENV-1: Dengue virus type-1;
DENV-2: Dengue virus type-2; DENV-3: Dengue virus type-3; DENV-4: Dengue
Abdul Ahmad et al. Virology Journal  (2017) 14:229 Page 11 of 13
virus type-4; DHF: Dengue hemorrhagic fever; E: Envelope; FBS: Fetal bovine
serum; h: Hour; HBV: Hepatitis B virus; HEPES: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; HIV: Human immunodeficiency virus;
HSV: Herpes simplex virus; IC50: Half maximal inhibitory concentration; LCMS/
MS: Liquid chromatography tandem mass spectrometry; M: Membrane;
M: Molar; mAb: Monoclonal antibody; MEM: Minimum essential medium;
MIC: Minimum inhibitory concentration; mRNA: Messenger Ribonucleic acid;
MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5, diphenyltetrazoliumbromide;
NaOH: Sodium hydroxide; OD: Optical density; PBS: Phosphate buffered
saline; p.i.: Post-infection; PFU: Plaque forming unit; qRT-PCR: Quantitative
real time RT-PCR; rE-DIII: Recombinant E domain III protein; RT-PCR: Reverse
transcription polymerase chain reaction; WHO: World Health Organization
Acknowledgements
The authors thank Prof. Sazaly Abu Bakar of the University of Malaya,
Malaysia for providing the DENV-2 strain used in this study.
Funding
This study was supported by Seed Grant 2014–2016 of the Infectious
Diseases and Health Cluster, Tropical Medicine and Biology Platform,
Monash University Malaysia. Ms. Siti Aisyah was supported by the Jeffery
Cheah School of Medicine and Health Sciences, Monash University
Malaysia Scholarship Program.
Availability of data and materials
Not applicable.
Authors’ contributions
SAAA carried out the study and drafted the manuscript. UP provided the
material fundamental to the study and edited the manuscript. BAT
conducted the docking part of the study. CMF and THW helped carried out
the study. SSH conceived the study, provided funding support and helped
drafted the manuscript. All authors read and approved the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Virus-Host Interaction Research Group, Jeffrey Cheah School of Medicine
and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan,
47500 Bandar Sunway, Selangor, Malaysia. 2Department of Chemistry,
Universiti Putra Malaysia, 43400 Serdang, Malaysia. 3Faculty of Applied
Sciences, UCSI University, No. 1, Jalan Menara Gading, UCSI Heights, 56000
Kuala Lumpur, Cheras, Malaysia. 4Research Centre for Biomedical Sciences,
Sunway University, 47500 Bandar Sunway, Selangor, Malaysia. 5Faculty of
Pharmacy, SEGI University, 9 Jalan Teknologi, Taman Sains Selangor, PJU 5,
Kota Damansara, 47810 Petaling Jaya, Selangor, Malaysia. 6Infectious Diseases
and Health Cluster, Tropical Medicine and Biology Platform, Monash
University Malaysia, Bandar Sunway 47500, Selangor, Malaysia.
Received: 9 August 2017 Accepted: 13 November 2017
References
1. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;
496(7446):504–7.
2. Gubler, D.J., Dengue Viruses, in Encyclopedia of Virology (Third Edition),
B.W.J. Mahy and M.H.V.V. Regenmortel, Editors. 2008, Academic Press:
Oxford. p. 5–14.
3. World Health Organization. Dengue: guidelines for diagnosis, treatment,
prevention and control: New Edition. Geneva; 2009. Available from http://
www.who.int/rpc/guidelines/9789241547871/en/.
4. Hung S-L, et al. Analysis of the steps involved in dengue virus entry into
host cells. Virology. 1999;257(1):156–67.
5. Whitehorn J, Farrar J. Dengue. Br Med Bull. 2010;95:161–73.
6. Ocazionez RE, et al. Virucidal activity of Colombian Lippia essential oils on
dengue virus replication in vitro. Mem Inst Oswaldo Cruz. 2010;105:304–9.
7. Patkar, C.G. and R.J. Kuhn, Development of novel antivirals against
Flaviviruses, in New Treatment Strategies for Dengue and Other Flaviviral
Diseases. 2008, John Wiley & Sons, Ltd. p. 41–56.
8. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: entry as a
target for antiviral drug design. Antivir Res. 2008;80(1):11–22.
9. Rey FA. Dengue virus: two hosts, two structures. Nature. 2013;497(7450):443–4.
10. Kaptein SJF, Neyts J. Towards antiviral therapies for treating dengue virus
infections. Curr Opin Pharmacol. 2016;30:1–7.
11. Parida MM, et al. Inhibitory potential of neem (Azadirachta Indica Juss) leaves
on dengue virus type-2 replication. J Ethnopharmacol. 2002;79(2):273–8.
12. Lee S, et al. Effects of cocktail of four local Malaysian medicinal plants
(Phyllanthus spp.) against dengue virus 2. BMC Complement Altern Med.
2013;13(1):192.
13. Jassim SAA, Naji MA. Novel antiviral agents: a medicinal plant perspective.
J Appl Microbiol. 2003;95(3):412–27.
14. Ong PK, Acree TE, Lavin EH. Characterization of volatiles in Rambutan fruit
(Nephelium Lappaceum L.). J Agric Food Chem. 1998;46(2):611–5.
15. Palanisamy UD, et al. Rapid isolation of geraniin from Nephelium
Lappaceum rind waste and its anti-hyperglycemic activity. Food Chem.
2011;127(1):21–7.
16. Ito H. Metabolites of the ellagitannin geraniin and their antioxidant
activities. Planta Med. 2011;77(11):1110–5.
17. Lipińska, L., E. Klewicka, and M. Sójka, The structure, occurrence and
biological activity of ellagitannins: a general review. Acta Sci. Pol., Technol.
Aliment, 2014. 13(3): p. 289–299.
18. Yang CM, et al. The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-
beta-D-glucose isolated from Phyllanthus Urinaria against herpes simplex
virus type 1 and type 2 infection. J Ethnopharmacol. 2007;110(3):555–8.
19. Notka F, Meier GR, Wagner R. Inhibition of wild-type human
immunodeficiency virus and reverse transcriptase inhibitor-resistant variants
by Phyllanthus Amarus. Antivir Res. 2003;58(2):175–86.
20. Li J, et al. In vitro and in vivo anti-hepatitis B virus activities of a plant
extract from Geranium Carolinianum L. Antivir Res. 2008;79(2):114–20.
21. Yang Y, et al. Antiviral effect of geraniin on human enterovirus 71 in vitro
and in vivo. Bioorg Med Chem Lett. 2012;22(6):2209–11.
22. Phillips ML. Dengue reborn: widespread resurgence of a resilient vector.
Environ Health Perspect. 2008;116(9):A382–8.
23. Perry ST, Buck MD, Shresta S. Better late than never: antivirals for dengue.
Expert Rev Anti-Infect Ther. 2011;9(7):755–7.
24. Canard B. Antiviral research and development against dengue virus. 2010 8
August 2012]; Available from: http://www.who.int/tdr/research/ntd/dengue/
dengue_full_length_report.pdf.
25. Perera A, et al. Large scale purification of geraniin from Nephelium
Lappaceum rind waste using reverse-phase chromatography. Sep Purif
Technol. 2012;98(0):145–9.
26. Javed T, et al. In-vitro antiviral activity of Solanum Nigrum against hepatitis
C virus. Virol J. 2011;8:26.
27. Meneses R, et al. Inhibitory effect of essential oils obtained from plants
grown in Colombia on yellow fever virus replication in vitro. Ann Clin
Microbiol Antimicrob. 2009;8:8.
28. Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of
casuarinin from the bark of Terminalia Arjuna Linn. Antivir Res. 2002;
55(3):447–55.
29. Daelemans D, et al. A time-of-drug addition approach to target
identification of antiviral compounds. Nat Protoc. 2011;6(6):925–33.
30. Wang QY, et al. A small-molecule dengue virus entry inhibitor. Antimicrob
Agents Chemother. 2009;53(5):1823–31.
31. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of
docking with a new scoring function, efficient optimization and
multithreading. J Comput Chem. 2010;31(2):455–61.
32. Davenport A, Russell F. Radioligand binding assays: theory and practice. In:
Mather S, editor. Current Directions in Radiopharmaceutical Research and
Development. Netherlands: Springer; 1996. p. 169–79.
Abdul Ahmad et al. Virology Journal  (2017) 14:229 Page 12 of 13
33. Okuda T, Yoshida T, Nayeshiro H. Geraniin, a new ellagitannin from
Geranium Thunbergii. Tetrahedron Lett. 1976;17:3721–2.
34. Cheng HS, Ton SH, Abdul Kadir K. Ellagitannin geraniin: a review of the
natural sources, biosynthesis, pharmacokinetics and biological effects.
Phytochem Rev. 2016:1–35.
35. Vaughn DW, et al. Dengue viremia titer, antibody response pattern, and
virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.
36. Chee H-Y, AbuBakar S. Phylogenetic investigation of dengue virus type 2
isolated in Malaysia. Dengue Bulletin. 2003;27:100–7.
37. Shors, T., Virus replication cycles, in Understanding viruses (Second edition).
2013, Jones & Bartlett learning: Burlington, MA. p. 46–69.
38. Galabov, A.S., Virucidal agents in the eve of manorapid synergy. GMS
Krankenhhyg Interdiszip, 2007. 2(1): p. Doc18.
39. Perera A, Ton SH, Palanisamy UD. Perspectives on geraniin, a multifunctional
natural bioactive compound. Trends Food Sci Technol. 2015;44(2):243–57.
40. Seema and S.K. Jain, Molecular mechanism of pathogenesis of dengue virus:
Entry and fusion with target cell. Indian J Clin Biochem, 2005. 20(2): p. 92–103.
41. Weaver JL, et al. Prevention of binding of rgp120 by anti-HIV active tannins.
Biochem Pharmacol. 1992;43(11):2479–80.
42. Low JS, et al. Narasin, a novel antiviral compound that blocks dengue virus
protein expression. Antivir Ther. 2011;16(8):1203–18.
43. van der Schaar HM, et al. Characterization of the early events in dengue
virus cell entry by biochemical assays and single-virus tracking. J Virol.
2007;81(21):12019–28.
44. Acosta EG, Talarico LB, Damonte EB. Cell entry of dengue virus. Futur Virol.
2008;3(5):471–9.
45. Bielefeldt-Ohmann H, et al. Dengue virus binding to human leukocyte cell
lines: receptor usage differs between cell types and virus strains. Virus Res.
2001;73(1):81–9.
46. Hidari KIPJ, Suzuki T. Dengue virus receptor. Tropical Medicine and Health.
2011;39(4 Suppl):37–43.
47. Modis Y, et al. A ligand-binding pocket in the dengue virus envelope
glycoprotein. Proc Natl Acad Sci U S A. 2003;100(12):6986–91.
48. Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus
envelope protein to target cells. J Virol. 1996;70(12):8765–72.
49. Mairiang D, et al. Identification of new protein interactions between dengue
fever virus and its hosts, human and mosquito. PLoS One. 2013;8(1):e53535.
50. Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue
virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007;9(1):1–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Abdul Ahmad et al. Virology Journal  (2017) 14:229 Page 13 of 13
